Salmonella HUE-C634 strain, construction method and application thereof
The dual-gene deletion strain Salmonella HUE-C634, constructed through genetic engineering technology, solved the problem of low safety of the existing Salmonella enteritis vaccine, achieved the effect of significantly reducing virility and improving immune protection, and provided a safer vaccine choose.
Patent Information
- Application Number
- CN202411122471.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The safety of the existing Salmonella enteritis vaccine is not high enough, especially the live attenuated vaccine becomes randomly mutated through natural passage or chemical randomization, the genetic background is unclear, and there is a safety risk.
The greA and greB genes of the standard Salmonella enteritidis were knocked out through genetic engineering technology, and the attenuated strain Salmonella HUE-C634, which was deleted by the two gene, was constructed to prepare a vaccine, significantly reducing virility and improving safety.
The constructed attenuated strain HUE-C634 significantly reduced virility, no adverse reactions after vaccination, can be quickly cleared from the host, provide good immune protection, and does not affect the normal growth and development of the chickens, significantly improving the safety of the vaccine. Sexual and immune effects.
Smart Images

Figure CN118909901A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of microbial technology, and more specifically to a Salmonella HUE-C634 strain, a construction method and an application thereof. Background Art
[0002] Salmonella enteritidis, also known as Salmonella enteritidis in Latin, is a Gram-negative, intracellular pathogen that can cause gastrointestinal diseases and even systemic infections in humans and a variety of animals. Infected chickens are an important source of infection for Salmonella enteritidis, which can enter the human food production chain through eggs, poultry meat and related products. This has a serious impact on human public health safety. The prevention and control of Salmonella enteritidis has become an important issue in the fields of medicine, veterinary medicine and public health. The prevention and control of Salmonella usually relies on antibiotics, but the abuse of antibiotics has led to the continuous increase in Salmonella resistance, and the emergence of multi-drug resistant strains has led to a decrease in the effectiveness of antibiotic treatment. If resistant bacteria are widely spread in farmed animals, farmed animals will become a large reservoir of drug-resistant genes. In recent years, vaccines have become a new option for many countries to prevent and control salmonellosis.
[0003] There are many types of enteritis Salmonella vaccines available. Compared with inactivated vaccines, live attenuated vaccines have the characteristics of inducing cellular, mucosal and humoral immunity, and can also reproduce in immunized animals, with a longer immunity period. However, at present, live attenuated vaccines for salmonellosis are often obtained through natural passage or chemical random mutation, and their genetic background is unclear, which leads to the problem of insufficient safety. Summary of the invention
[0004] To solve the above problems, the present invention provides a Salmonella HUE-C634 strain, a construction method and an application thereof, which solve the problem that the safety of Salmonella enteritidis strains in the prior art is not high enough.
[0005] The present invention is achieved through the following technical solutions:
[0006] The present invention provides a Salmonella (Salmonella.sp) HUE-C634 strain, which was deposited in the China Center for Type Culture Collection on July 1, 2024, with a deposit number of CCTCC M20241412.
[0007] The construction method of the Salmonella HUE-C634 strain is as follows:
[0008] S1: Use greA gene knockout primers and pKD3 plasmid as template to perform PCR to obtain greA gene knockout PCR products; use greB gene knockout primers and pKD3 plasmid as template to perform PCR to obtain greB gene knockout PCR products;
[0009] S2: Preparation of competent cells of the standard strain of Salmonella Enteritidis using arabinose induction;
[0010] S3: The greA gene knockout PCR product in S1 was transformed into competent cells of the standard strain of Salmonella Enteritidis by electroporation, and the positive clone SEATCC13076greA::cat was screened;
[0011] S4: The pCP20 plasmid was electroporated into SEATCC13076greA::cat to construct the Salmonella Enteritidis greA gene deletion strain SEATCC13076ΔgreA;
[0012] S5: Using the single gene deletion strain SEATCC13076ΔgreA as the initial strain, the greB gene was knocked out using the PCR product according to the methods of S2 to S4 to obtain the target strain Salmonella HUE-C634.
[0013] Preferably, the standard strain of Salmonella Enteritidis includes but is not limited to: Salmonella Enteritidis ATCC13076.
[0014] The greA gene sequence is shown in SEQ ID NO.1; the greB gene sequence is shown in SEQ ID NO.2.
[0015] The invention relates to an application of the Salmonella HUE-C634 strain in the preparation of medicines for preventing enteritis Salmonella.
[0016] A vaccine for preventing enteritidis Salmonella, wherein the vaccine composition comprises the Salmonella HUE-C634 strain or a culture thereof.
[0017] Preferably, the active ingredient of the vaccine is the Salmonella HUE-C634 strain or a culture thereof.
[0018] Preferably, the vaccine further comprises conventional auxiliary components for preparing vaccines.
[0019] A live vaccine to protect against Salmonella Enteritidis.
[0020] Preferably, a single colony of the Salmonella HUE-C634 strain is inoculated into a culture medium and cultured for 16 to 18 hours, and then the culture is taken out and the bacterial solution product is diluted in a gradient ratio.
[0021] Preferably, the culture medium is LB medium;
[0022] The gradient ratio is to dilute 10 times to a concentration of 1.74×10 9 CFU / ml or 1.74×10 11 CFU / ml.
[0023] Compared with the prior art, the present invention has the following beneficial effects:
[0024] The present invention utilizes genetic engineering technology to knock out the virulence genes greA and greB related to the standard strain of Enteritidis Salmonella, and constructs an attenuated strain Salmonella HUE-C634 with double gene deletion of Enteritidis Salmonella. Animal experiments show that the virulence of the mutant strain is significantly reduced, and the chickens have no adverse reactions after inoculation. The mutant is cleared quickly in the host body, and can be completely cleared in 1 to 2 weeks, and has excellent safety. The avian Enteritidis Salmonella live vaccine prepared by the attenuated strain has significantly lower virulence than the standard strain of Enteritidis Salmonella. After inoculation of the Enteritidis Salmonella live attenuated vaccine of the present invention, the avian vaccine has good immunogenicity and immune protection, and has no effect on the daily weight gain of the chickens after immunization, does not affect the normal growth and development of the chickens, and can provide a solid immune protection effect for the chicks. Therefore, the attenuated vaccine developed by the present invention is of great significance for preventing and controlling the infection of Enteritidis Salmonella.
[0025] Biomaterial Deposit
[0026] The Salmonella HUE-C634 strain was deposited in the China Center for Type Culture Collection on July 1, 2024, with the deposit number CCTCC M 20241412, and the deposit address is Wuhan, China. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0028] Figure 1 This is the PCR identification result after knocking out greA gene and greB gene;
[0029] Figure 2 is the growth curve of Salmonella HUE-C634 strain;
[0030] Figure 3 The PCR identification results of greA gene and greB gene;
[0031] Figure 3 In the figure, A is the PCR identification result of greA gene; B is the PCR identification result of greB gene;
[0032] Figure 4 The results of the biosafety evaluation of Salmonella HUE-C634 strain;
[0033] Figure 4 In the figure, A is the body weight gain after immunization; B is the bacterial load in the spleen; C is the bacterial load in the liver;
[0034] Figure 5 This is the evaluation result of the vaccine effect of Salmonella HUE-C634 strain;
[0035] Figure 5 In the figure, A is the body weight gain after challenge; B is the bacterial load in the spleen; C is the bacterial load in the liver. DETAILED DESCRIPTION
[0036] In order to facilitate the understanding of the present invention, the present invention will be described more comprehensively below, and preferred embodiments of the present invention are provided. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.
[0037] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the specification of the present invention herein are only for the purpose of describing specific embodiments and are not intended to limit the present invention.
[0038] The invention provides a Salmonella enteritidis greA and greB double gene deleted strain Salmonella HUE-C634 strain, wherein the gene deleted strain does not contain greA and greB genes, and the deposit number is CCTCC M20241412. The Salmonella enteritidis greA and greB double gene deleted strain is selected as the Salmonella enteritidis in which the greA and greB genes are not expressed at the same time.
[0039] The specific usable Salmonella enteritidis standard strains include but are not limited to: Salmonella enteritidis ATCC13076. The source of the Salmonella enteritidis standard strain ATCC13076 is: China Medical Microbiological Culture Collection Administration Center, with the collection number ATCC13076.
[0040] The deleted greA gene sequence is shown in SEQ ID NO.1; the deleted greB gene is shown in SEQ ID NO.2. The attenuated strain may also undergo other genetic modifications. The other genetic modifications refer to genetic modifications other than the deletion of greA and greB genes, which may be modifications of a single target gene or multiple target genes. The target gene is not specific and can be set and modified according to research needs. In theory, it can be genetically modified continuously, and the number of modifications to the target gene can be operated as needed without special restrictions. Genetic modification methods include, but are not limited to, insertion and deletion of target genes.
[0041] SEQ ID NO.1
[0042] ttaaaggtattccactttaagcacttcgtattccacatcgccgccaggcgttttgatcaccacgacgtcatcctgctctttgccgatcaggccgcgagcgattggcgagtttaccgaaatgagattttgcttaaaatccgcctcatcatcgccaacaatgcggtaggtctgctcttcgtcggtgtccaggttcagcaccgtgacggtagcgccgaaaatcacgcggccattgttcggcattttagtgacatcaatcacctgcgcattcgacagttttgcttcgatatctttaatgcgcccttcgcagaaaccctgctgttcgcgtgcagcatgatactccgcgttttcttttaaatcgccatgttcgcgcgcttcggcgatagcggcgatgatttcaggacggcgcacagatttcagaaaatccagctcttcgcgcagtttttcggctccgcgtaaggtcatcggaatagcttgcat
[0043] SEQ ID NO.2
[0044] atgaaaacgcccctgatcacccgcgaagggtacgaaacactcaaacaagagctcaattatctctggcgtgaagagcgcccggaggtcaccaaaaaagtgacctgggctgcgagtctgg gcgaccgcagcgagaatgccgactatcagtataataaaaagcgcctgcgtgagatcgacagacgcgtcagatatctgaccaaatgcatggaaaatctcaaaatcgtggattattccccg cagcaggagggcaaagtcttcttcggcgcctgggtggaaattgaaaatgatgacggcgatacgctgaagttccgcattgtcggctacgatgaaattttcggacgtaaggattacatct ctatcgactcgccgatggcgcgggcgctactgaaaaaagaagtgggcgatctggcggtggtcaacacccctgtcggcgaagcaaactggtacgtcaatgcgatcgaatacgtcaaataa
[0045] Example 1: Construction method of Salmonella HUE-C634 strain
[0046] (1) Based on the greA and greB gene sequences of Salmonella Enteritidis on NCBI GenBank, primers for knocking out the greA and greB genes were designed, as shown in Table 1. PCR was performed using the greA gene knockout primers and the pKD3 plasmid as a template to obtain a greA gene knockout PCR product; PCR was performed using the greB gene knockout primers and the pKD3 plasmid as a template to obtain a greB gene knockout PCR product.
[0047] (2) Preparation of Salmonella Enteritidis ATCC13076 competent cells by arabinose induction.
[0048] (3) The greA gene knockout PCR product was transformed by electroporation into Salmonella Enteritidis ATCC13076 competent cells to replace the greA gene, and the cells were spread on chloramphenicol resistant plates. After screening, the positive clone SEATCC13076greA::cat with greA replaced was obtained. The obtained positive clone SE ATCC13076greA::cat was cultured on a non-resistant plate and purified at 37°C. Then, the ampicillin resistance was tested to determine whether the plasmid was lost. If the plasmid was not lost, the bacteria were purified at 43°C and the ampicillin resistance was tested again.
[0049] (4) The temperature-sensitive plasmid pCP20 was then electroporated into SEATCC13076greA::cat to eliminate the chloramphenicol resistance gene, and positive clones were screened at 30°C on an LB plate containing ampicillin, and then the positive clones were purified at 43°C to detect antibiotic resistance. The construction of the Salmonella Enteritidis greA deletion strain was verified by PCR specific detection, and the Salmonella Enteritidis single gene deletion strain SE ATCC13076ΔgreA was obtained.
[0050] (5) Using the single gene deletion strain SEATCC13076ΔgreA as the initial strain, the greB gene was knocked out using the PCR product of the greB gene according to the above method to obtain the target strain SEATCC13076ΔgreAgreB. Figure 1 As shown, SEATCC13076 agarose gel electrophoresis obtained the expected 500 bp target band pattern, and the gene deletion strain had no band.
[0051] (6) The target strain SEATCC13076ΔgreAgreB was passaged several times, and the deletion strain with stable properties and fast growth rate was selected as the vaccine strain to be screened. The attenuated strain finally screened was named Salmonella.sp HUE-C634 strain.
[0052] Table 1 Primer sequence list for greA and greB gene knockout
[0053]
[0054] Example 2, determination of growth curve of Salmonella HUE-C634 strain
[0055] (1) Comparison of the growth of Salmonella enteritidis SE ATCC13076 and its derivatives. SE ATCC13076 and its derivatives were selected and cultured overnight in liquid LB at 37°C and 160 r / min. The overnight cultures of Salmonella enteritidis SE ATCC13076 and its derivatives were inoculated into sterilized 100 mL LB broth at a ratio of 1:100. 2 mL was aspirated from each and the absorbance at 600 nm was measured using a spectrophotometer, i.e., OD 600 The reading at this time is recorded as 0h, and the OD of the culture is monitored every 1h using a spectrophotometer. 600 , and then measure every 2 hours after 6 hours for 24 hours continuously; each time, adjust to zero with sterile LB broth, and repeat the test 3 times. Figure 2 As shown, the results showed that the growth rate of the Salmonella HUE-C634 strain was not affected compared with the wild strain, thus ensuring that the gene-deficient strain could be used for large-scale growth.
[0056] (2) The Salmonella HUE-C634 strain was subcultured, and a single colony of each generation of the strain was used as a template for PCR amplification using a primer pair. The primer sequences are shown in Table 2. The expected target bands of 500 bp in size were obtained by agarose gel electrophoresis. The experimental results are shown in Table 2. Figure 3 As shown, it is consistent with the expected result, indicating that the gene deletion strains of Salmonella Enteritidis can be stably inherited.
[0057] Table 2 Identification primer sequences
[0058] name Primer sequence (5'-3') SEQ ID NO.11 TATACTGGTGGTCAATCCGATGA SEQ ID NO.12 ACGCTGGTGCTGTATCGC SEQ ID NO.13 GCAATAATGCGGCAGAAAGA SEQ ID NO.14 AGCCCTGCTCGGTCAGATAA
[0059] Example 3: Biosafety evaluation of Salmonella HUE-C634 strain
[0060] First, Salmonella Enteritidis SE ATCC13076 and its derivatives were densely streaked onto non-antibiotic LB solid plate medium and incubated at 37°C for 24 h. The bacteria were washed and scraped with sterile phosphate buffered saline (PBS) and a sterile coating rod, collected in a 50 mL sterile centrifuge tube, and washed twice with 40 mL sterile PBS at 10,000 r / min for 20 min. The bacterial precipitate was thoroughly resuspended with an appropriate amount of sterile PBS, and the OD was adjusted to 0.3. The bacterial content of the original solution was calculated. The Salmonella HUE-C634 bacterial solution was diluted 10 times to 1.38×10 9 CFU / mL, 1.38×10 10 CFU / mL; dilute the SEATCC13076 bacterial solution to 3.50×10 9 CFU / mL is prepared for subsequent animal oral infection experiments and live bacteria counts.
[0061] 120 0-day-old Hy-Line brown chicks were randomly divided into three groups: Group I, which was infected with Salmonella HUE-C634 at an infection dose of 2.76×10 8 CFU / unit; Experiment II, namely Salmonella HUE-C634, infection dose was 2.76×10 9 CFU / mouse; test group III, i.e. SEATCC13076, infection dose was 7×10 8 CFU / mouse. 40 mice per group.
[0062] The observation was continued for 28 days, and the clinical symptoms were recorded. The results showed that there was no significant difference in the weight of the Hy-Line Brown chickens in each group. The bacterial load in the organs of the wild ATCC13076 strain of Hy-Line Brown chickens in the oral challenge control group was higher than that in the Salmonella HUE-C634 experimental group at two different concentrations. Figure 4 It is shown that the strain Salmonella HUE-C634 screened by the present invention has good biosafety.
[0063] Example 4: Preparation of vaccine using Salmonella HUE-C634 strain
[0064] (1) Preparation of live vaccine: Salmonella HUE-C634 strains were densely streaked on LB plates, with 3 plates for each strain prepared. The plates were cultured at 37°C for 17 h. The next day, the bacteria were washed and scraped off with sterile PBS and a sterile spreader stick, collected in a 50 mL sterile centrifuge tube, and sterile PBS was added to 30 mL. The tube was washed twice at 10,000 r / min for 20 min. The precipitate was thoroughly resuspended with an appropriate amount of sterile PBS, and the OD was adjusted to 0.3. The bacterial content of the stock solution was calculated and diluted 10 times to 1.74 × 10 9 CFU / ml, 1.74×10 11 CFU / ml was kept for later use and live bacteria count was performed.
[0065] (2) Vaccine immune effect A total of 120 0-day-old Hy-Line brown chicks were randomly divided into three groups: Group I, which was Salmonella HUE-C634, with an immunization dose of 10 9 CFU / mL, 0.2mL / animal, test group II, namely Salmonella HUE-C634, immunization dose of 10 11 CFU / mL, 0.2mL / bird, control group, i.e. PBS. Each group of 40 birds were immunized by oral dripping. Water was cut off for half a day before immunization. The conditions of each group were observed and recorded. After 21 days of immunization, the experimental group and the control group were challenged with wild-type SEATCC13076. 1d, 3d, 5d, 7d, 14d, and 28d after the challenge, the weight gain, incidence, liver and spleen bacterial counts, and antibody levels of each group of experimental chickens were recorded. The experimental results are shown in Figure 5 shown.
[0066] The above experimental results show that the vaccine prepared by the Salmonella HUE-C634 strain of the present invention can provide complete protection against infection by the wild SEATCC13076 strain, and the experimental animals in this group did not show any clinical symptoms and there was no death.
[0067] In summary, the Salmonella HUE-C634 strain of the present invention utilizes Red homologous recombination technology to delete the greAgreB gene in the genome of Salmonella Enteritidis SEATCC13076, maintaining good immunogenicity. Animal experiments have shown that the vaccine is safe for chickens, can induce the production of higher neutralizing antibodies, has good protective effects, and has broad application prospects.
[0068] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0069] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A Salmonella.sp HUE-C634 strain, characterized in that: The strain was deposited in the China Center for Type Culture Collection on July 1, 2024, with the deposit number CCTCC M20241412.
2. The method for constructing the Salmonella HUE-C634 strain according to claim 1, characterized in that: The specific construction method is as follows: S1: Use greA gene knockout primers and pKD3 plasmid as template to perform PCR to obtain greA gene knockout PCR products; use greB gene knockout primers and pKD3 plasmid as template to perform PCR to obtain greB gene knockout PCR products; S2: Preparation of competent cells of the standard strain of Salmonella Enteritidis using arabinose induction; S3: The greA gene knockout PCR product in S1 was transformed into competent cells of the standard strain of Salmonella Enteritidis by electroporation, and the positive clone SEATCC13076greA::cat was screened; S4: The pCP20 plasmid was electroporated into SEATCC13076greA::cat to construct the Salmonella Enteritidis greA gene deletion strain SEATCC13076ΔgreA; S5: Using the single gene deletion strain SEATCC13076ΔgreA as the initial strain, the greB gene was knocked out using the PCR product according to the methods of S2 to S4 to obtain the target strain Salmonella HUE-C634.
3. The method for constructing the Salmonella HUE-C634 strain according to claim 2, characterized in that: The standard strain of Salmonella Enteritidis includes but is not limited to: Salmonella Enteritidis ATCC13076.
4. The method for constructing the Salmonella HUE-C634 strain according to claim 2, characterized in that: The greA gene sequence is shown in SEQ ID NO.1; the greB gene sequence is shown in SEQ ID NO.
2.
5. Use of the Salmonella HUE-C634 strain as claimed in claim 1 in the preparation of medicines for preventing enteritis Salmonella.
6. A vaccine for preventing enteritidis Salmonella, characterized in that: The active ingredient comprises the Salmonella HUE-C634 strain or the culture thereof as claimed in claim 1.
7. The vaccine for preventing enteritidis Salmonella according to claim 6, characterized in that: The active ingredient is the Salmonella HUE-C634 strain or its culture.
8. The vaccine for preventing Salmonella enteritidis according to claim 6 or 7, characterized in that: Conventional auxiliary ingredients used in the preparation of vaccines are also included.
9. A live vaccine for preventing enteritidis Salmonella, characterized in that: A single colony of the Salmonella HUE-C634 strain according to claim 1 is inoculated into a culture medium and cultured for 16 to 18 hours, then the culture is taken out and the bacterial solution product is diluted in a gradient ratio to obtain a live vaccine.
10. The live vaccine for preventing Salmonella enteritidis according to claim 9, characterized in that: The culture medium is LB culture medium; The gradient ratio is to dilute 10 times to a concentration of 1.74×10 9 CFU / ml or 1.74×10 11 CFU / ml.
